Centene (NYSE:CNC) Given New $55.00 Price Target at UBS Group

Key Points

• UBS raised its price target on Centene to $55 (from $42) while keeping a "neutral" rating, implying only about a 4.6% upside from the recent share price.
• Q1 beat and guidance lift: Centene reported EPS of $3.37 vs. ~$2.12 expected and revenue of $49.94B, prompting a share jump to about $52.60 as management cited cost controls and stronger Medicaid performance.
• Analyst views remain mixed — the consensus is a Hold with a $49.76 target amid a wide range of price calls and upgrades, while risks include a ~2 million drop in ACA enrollment, persistent commercial membership weakness, and recent insider/institutional rebalancing.

Centene (NYSE:CNC - Get Free Report) had its target price boosted by equities researchers at UBS Group from $42.00 to $55.00 in a research note issued on Wednesday,MarketScreener reports. The firm currently has a "neutral" rating on the stock. UBS Group's price objective points to a potential upside of 4.56% from the company's current price.

A number of other research analysts have also commented on CNC. Raymond James Financial set a $60.00 price objective on shares of Centene in a research note on Wednesday. TD Cowen lifted their price target on Centene from $34.00 to $38.00 and gave the company a "hold" rating in a research report on Wednesday, February 11th. Bank of America raised Centene from an "underperform" rating to a "buy" rating and boosted their price objective for the stock from $34.00 to $60.00 in a research note on Wednesday. Oppenheimer reaffirmed an "outperform" rating and set a $58.00 target price on shares of Centene in a research note on Wednesday. Finally, Robert W. Baird upped their price target on shares of Centene from $36.00 to $37.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Centene presently has a consensus rating of "Hold" and a consensus target price of $49.76.

Centene Stock Performance

Shares of CNC traded up $3.03 during mid-day trading on Wednesday, reaching $52.60. 2,817,833 shares of the company's stock traded hands, compared to its average volume of 6,445,257. Centene has a 12 month low of $25.08 and a 12 month high of $64.15. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.10 and a current ratio of 1.10. The stock has a market capitalization of $25.87 billion, a P/E ratio of -3.89, a price-to-earnings-growth ratio of 0.96 and a beta of 0.59. The business's 50-day moving average price is $38.49 and its 200-day moving average price is $39.24.

Centene (NYSE:CNC - Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The company reported $3.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $1.25. The company had revenue of $49.94 billion during the quarter, compared to analysts' expectations of $47.58 billion. Centene had a positive return on equity of 4.25% and a negative net margin of 3.43%.The company's revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.90 earnings per share. Equities analysts predict that Centene will post 3.01 earnings per share for the current year.

Institutional Investors Weigh In On Centene

Several hedge funds have recently bought and sold shares of CNC. AQR Capital Management LLC boosted its position in Centene by 117.0% during the 4th quarter. AQR Capital Management LLC now owns 31,798,738 shares of the company's stock worth $1,308,518,000 after acquiring an additional 17,143,904 shares during the period. Norges Bank purchased a new stake in shares of Centene in the fourth quarter worth approximately $332,044,000. Deerfield Management Company L.P. boosted its holdings in shares of Centene by 184.0% during the third quarter. Deerfield Management Company L.P. now owns 9,046,000 shares of the company's stock worth $322,761,000 after purchasing an additional 5,860,630 shares during the period. 8 Knots Management LLC purchased a new position in Centene during the third quarter valued at approximately $186,662,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Centene by 52.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,171,568 shares of the company's stock valued at $295,111,000 after buying an additional 2,472,341 shares during the period. 93.63% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Centene

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — Centene reported adjusted EPS well above estimates ($3.37 vs. consensus ~ $2.12), revenue beat, and raised 2026 EPS guidance after improving medical-cost controls. This is the primary driver of the stock move. PR Newswire
• Positive Sentiment: Cost controls + Medicaid strength — Management cited declining medical costs and stronger Medicaid performance, improving margins and lifting investor confidence in near-term profitability. Reuters
• Positive Sentiment: Bank of America upgraded CNC to Buy with a $60 price target (from $34), backing the rebound story and providing further buy-side support. Benzinga
• Positive Sentiment: Unusual bullish options flow — Large purchases of call options (≈19,116 contracts) indicate short-term speculative/hedge positioning ahead of/after the print (possible short-covering or directional bets).
• Neutral Sentiment: Earnings-call tone mixed — The Q1 call showed strong results but a cautious management tone on outlook details and membership trends; watch commentary for FY cadence. TipRanks
• Neutral Sentiment: Mixed analyst landscape — Some upgrades and higher targets (e.g., BofA) but a wide range of price targets and recent sell/hold calls leave consensus still mixed; volatility in estimates likely. QuiverQuant
• Negative Sentiment: ACA (Obamacare) enrollment drop — Reports show a ~2 million decline in individual-market enrollment after subsidy changes, a structural headwind for Centene’s individual business going forward. Forbes
• Negative Sentiment: Commercial enrollment slide persists — While Medicaid helped, commercial membership softness remains a risk to revenue growth and could temper margin gains. Benzinga
• Negative Sentiment: Insider selling and large institutional rebalancing — Recent insider stock sales and big fund position turnover could keep selling pressure at times. QuiverQuant

Centene Company Profile

Centene Corporation NYSE: CNC is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children's Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene's offerings extend beyond traditional insurance to include a range of specialty and support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.